NLRP3 inflammasome as a novel therapeutic target for heart failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35191381/
Heart failure (HF) is a leading cause of mortality worldwide. The pathogenesis of HF is complex and has not yet been fully elucidated, which has slowed drug development and long-term...
Relevance: In this study, we systematically summarize evidence regarding the relationship among NLRP3 inflammasome, energy metabolism, intestinal microflora metabolites, and inflammation, as well as highlight advantages of NLRP3 inflammasome in treating HF.
Share
Impact of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) On Cardiac Bioenergetic Properties and Cardiorespiratory Fitness: A Special Effect of SGLT2i In Heart Failure? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35191660/
Recent clinical trials have highlighted the profound benefits of Sodium-glucose linked transporter 2 inhibitors (SGLT2i) on cardiovascular mortality and hospitalization for heart failure patients. Modest improvements in glycemic, lipid or...
Conclusion/Relevance: In this review, we discuss the current evidence supporting a shift in myocardial substrate utilization from carbohydrates and fat oxidation towards energy efficient ketone bodies in the failing heart and the role of SGLT2i in this key metabolic adaptation to optimize myocardial fuel energetics. Further insights into the...
Share
Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35191586/
For the past two decades, heart failure (HF) has been classified into two phenotypes based on ejection fraction (EF). Inhibitors of the RAAS, neprilysin, , and beta-blockers represent foundational treatments...
Conclusion/Relevance: In the EMPEROR trials, empagliflozin reduced the risk of total HF hospitalizations by approximately 30% in patients with EF ranging from 60-65%. Since patients with an EF >60% represent only 10-15% of all HF patients, we propose that foundational HF treatments should be applied to patients across broad range of EF.
Share
Stopping Empagliflozin Unmasks Heart Failure
About 40% of patients with heart failure (HF) also have type 2 diabetes mellitus (T2DM). 1 Certain sodium-glucose cotransporter-2 (SGLT2) inhibitors have benefited patients with HF. 2 We report a...
Relevance: SGLT2 inhibitors have been shown to have a role in the management of heart failure in patients with type 2 diabetes mellitus, but there is a risk of exacerbation when discontinued.
Share
Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0263481
Purpose Results from large scale cardiovascular outcome trials in patients with type 2 diabetes mellitus (DM2) have found that sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular death and hospitalization for...
/>
Conclusions: Despite effect on weight-loss, Hba1c and biomarkers, treatment with empagliflozin for 12 weeks did not improve CFVR in patients with DM2.
Share